Steven Lim

Array ( [id] => 6478619 [patent_doc_number] => 20100285108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-11 [patent_title] => 'Method for therapeutic use' [patent_app_type] => utility [patent_app_number] => 12/661628 [patent_app_country] => US [patent_app_date] => 2010-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 28020 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0285/20100285108.pdf [firstpage_image] =>[orig_patent_app_number] => 12661628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6550010 [patent_doc_number] => 20100233156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-16 [patent_title] => 'Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors' [patent_app_type] => utility [patent_app_number] => 12/719282 [patent_app_country] => US [patent_app_date] => 2010-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9936 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0233/20100233156.pdf [firstpage_image] =>[orig_patent_app_number] => 12719282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5976802 [patent_doc_number] => 20110070613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-24 [patent_title] => 'Monoclonal Antibody' [patent_app_type] => utility [patent_app_number] => 12/701199 [patent_app_country] => US [patent_app_date] => 2010-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 38290 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0070/20110070613.pdf [firstpage_image] =>[orig_patent_app_number] => 12701199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9608223 [patent_doc_number] => 08785390 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-22 [patent_title] => 'Methods for treatment of Alzheimer\'s disease' [patent_app_type] => utility [patent_app_number] => 13/145096 [patent_app_country] => US [patent_app_date] => 2010-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 16353 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 207 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13145096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6195525 [patent_doc_number] => 20110027279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-03 [patent_title] => 'RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS, DNA ENCODING AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/691046 [patent_app_country] => US [patent_app_date] => 2010-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13234 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0027/20110027279.pdf [firstpage_image] =>[orig_patent_app_number] => 12691046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9250518 [patent_doc_number] => 08614297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-24 [patent_title] => 'Anti-idiotype antibody against an antibody against the amyloid β peptide' [patent_app_type] => utility [patent_app_number] => 12/637833 [patent_app_country] => US [patent_app_date] => 2009-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7518 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12637833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15135413 [patent_doc_number] => 10481167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-19 [patent_title] => Methods for measuring concentrations of biomolecules [patent_app_type] => utility [patent_app_number] => 13/132307 [patent_app_country] => US [patent_app_date] => 2009-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 10711 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 266 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13132307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8211189 [patent_doc_number] => 20120129782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-24 [patent_title] => 'Inhibition of ApoE Cleavage Activity in the Treatment of ApoE-Related Disorders' [patent_app_type] => utility [patent_app_number] => 13/130003 [patent_app_country] => US [patent_app_date] => 2009-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20584 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0129/20120129782.pdf [firstpage_image] =>[orig_patent_app_number] => 13130003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10007858 [patent_doc_number] => 09051364 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-09 [patent_title] => 'Composition for producing anti-amyloid beta peptide antibodies with D-peptides' [patent_app_type] => utility [patent_app_number] => 13/129579 [patent_app_country] => US [patent_app_date] => 2009-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 4544 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13129579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6000699 [patent_doc_number] => 20110117100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-19 [patent_title] => 'COMPOSITIONS AND METHODS FOR DIAGNOSIS, STRATIFICATION AND TREATMENT OF AMYLOIDOGENIC DISEASES' [patent_app_type] => utility [patent_app_number] => 12/611664 [patent_app_country] => US [patent_app_date] => 2009-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 12692 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0117/20110117100.pdf [firstpage_image] =>[orig_patent_app_number] => 12611664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10026095 [patent_doc_number] => 09067981 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-06-30 [patent_title] => 'Hybrid amyloid-beta antibodies' [patent_app_type] => utility [patent_app_number] => 12/608869 [patent_app_country] => US [patent_app_date] => 2009-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 40738 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12608869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10156817 [patent_doc_number] => 09188587 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-17 [patent_title] => 'Neurological autoimmune disorders' [patent_app_type] => utility [patent_app_number] => 13/125796 [patent_app_country] => US [patent_app_date] => 2009-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9799 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13125796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6262704 [patent_doc_number] => 20100297132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-25 [patent_title] => 'Monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 12/589570 [patent_app_country] => US [patent_app_date] => 2009-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 38284 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0297/20100297132.pdf [firstpage_image] =>[orig_patent_app_number] => 12589570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7510766 [patent_doc_number] => 20110256559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-20 [patent_title] => 'Method for Detecting Soluble Amyloid Precursor Protein (APP) Alpha and/or Soluble APP Beta' [patent_app_type] => utility [patent_app_number] => 13/124234 [patent_app_country] => US [patent_app_date] => 2009-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8090 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0256/20110256559.pdf [firstpage_image] =>[orig_patent_app_number] => 13124234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6466502 [patent_doc_number] => 20100040552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-02-18 [patent_title] => 'METHODS TO EVALUATE GLUCOCORTICOID RECEPTOR AGONISTS AND ANTAGONISTS FOR EFFECTS ON NEURON-LIKE CELLS' [patent_app_type] => utility [patent_app_number] => 12/579230 [patent_app_country] => US [patent_app_date] => 2009-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10652 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0040/20100040552.pdf [firstpage_image] =>[orig_patent_app_number] => 12579230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6177444 [patent_doc_number] => 20110178024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'AMYLOID BETA-PEPTIDES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/121421 [patent_app_country] => US [patent_app_date] => 2009-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 26316 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0178/20110178024.pdf [firstpage_image] =>[orig_patent_app_number] => 13121421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7757420 [patent_doc_number] => 20120029169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-02 [patent_title] => 'METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS' [patent_app_type] => utility [patent_app_number] => 13/060143 [patent_app_country] => US [patent_app_date] => 2009-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 14222 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0029/20120029169.pdf [firstpage_image] =>[orig_patent_app_number] => 13060143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11282684 [patent_doc_number] => 09498522 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-22 [patent_title] => 'Immunotherapeutic compositions for the treatment of alzheimer\'S disease' [patent_app_type] => utility [patent_app_number] => 13/057952 [patent_app_country] => US [patent_app_date] => 2009-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 9294 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13057952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8006049 [patent_doc_number] => 08084425 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-12-27 [patent_title] => 'Dopaminergic neuronal survival-promoting factors and uses thereof' [patent_app_type] => utility [patent_app_number] => 12/535029 [patent_app_country] => US [patent_app_date] => 2009-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 12750 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/084/08084425.pdf [firstpage_image] =>[orig_patent_app_number] => 12535029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6254637 [patent_doc_number] => 20100028918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-02-04 [patent_title] => 'GLUTAMINYL CYCLASE AS A DIAGNOSTIC/PROGNOSTIC INDICATOR FOR NEURODEGENERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 12/533099 [patent_app_country] => US [patent_app_date] => 2009-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9505 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0028/20100028918.pdf [firstpage_image] =>[orig_patent_app_number] => 12533099 [rel_patent_id] =>[rel_patent_doc_number] =>)